Baird raised the firm’s price target on Astrana Health (ASTH) to $86 from $67 and keeps an Outperform rating on the shares. The firm said the company’s largest acquisition to date, Prospect Health, adds incredible firepower to the company’s already-attractive long-term full-risk conversion story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH: